A5056488258- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pharmacy and Medical Practices
- Myasthenia Gravis and Thymoma
- Kruppel-like factors research
- Cancer Treatment and Pharmacology
- Pharmaceutical Practices and Patient Outcomes
- Bone health and treatments
- Electrolyte and hormonal disorders
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Breast Cancer Therapies
- Hemoglobinopathies and Related Disorders
- Chronic Myeloid Leukemia Treatments
- Pancreatic and Hepatic Oncology Research
- Eosinophilic Disorders and Syndromes
- Alcoholism and Thiamine Deficiency
- Medication Adherence and Compliance
- CAR-T cell therapy research
- Peripheral Neuropathies and Disorders
- Safe Handling of Antineoplastic Drugs
- Childhood Cancer Survivors' Quality of Life
- Bone and Joint Diseases
- Neurological and metabolic disorders
- Colorectal Cancer Treatments and Studies
Saitama International Medical Center
2020-2025
Saitama Medical University
2019-2025
Kyoto Prefectural University of Medicine
1987
Abstract Combination therapy with nivolumab and ipilimumab for advanced renal cell carcinoma (RCC) may cause immune-related myocarditis; however, its incidence in this cancer type regimen remains unknown. At our institution, we measure biomarkers, such as high-sensitivity Troponin (hsTn), perform electrocardiograms (ECGs) echocardiography before every month after the initiation of therapy, findings obtained patients’ symptoms are continuously monitored by physicians pharmacists. A...
Introduction Pembrolizumab cause immune‐related adverse events. We herein report a case of advanced bladder cancer, who treated with pembrolizumab and exhibited intriguing clinical course. Case presentation A 63‐year‐old man carcinoma was by radical cystectomy, however, the recurred invaded to rectum. He combination therapy using gemcitabine cisplatin, which were not effective for tumor. subsequently underwent treatment pembrolizumab. In several 30 days, he suffered from symptoms myasthenia...
Background: Pazopanib is an effective treatment option for renal cell carcinoma (RCC). However, the therapy often limited by appearance of adverse events (AEs), including nausea/vomiting, hepatic impairment, hand-foot syndrome, diarrhea, hypertension and oral mucositis. Early management AEs is, therefore, extremely important in order to maximize outcomes. Patients Methods: This non-randomized controlled before-and-after study was carried out evaluate effectiveness our comprehensive...
Abstract Background Nivolumab has become an effective treatment option for cancer in various sites; however, this drug may cause immune-related adverse effects due to its mechanism of action. Furthermore, little been reported on thiamine deficiency (TD) patients receiving nivolumab treatment. Method From a series patients, we patient with recurrent renal cell carcinoma who developed TD after the start Results A 74-year-old man was referred psycho-oncology department as he had lost about 4 kg...
Severe hypercalcemia (serum calcium, 4.25-5.25 mmol/l), in association with osteolytic bone lesions, was found a girl aged 2 yr 7 mo common acute lymphoblastic leukemia (ALL). Hormonal studies excluded the possibility of being caused by primary hyperparathyroidism or ectopic parathyroid hormone secretion. Increased plasma prostaglandin E2 (PGE2) levels (130 ng/l), probably produced leukemic cells, were considered to be one pathogenic mechanisms responsible for occurrence this patient. Both...
Introduction Pazopanib, a tyrosine kinase inhibitor, and nivolumab, an immune checkpoint are both considered to cause hepatotoxicity with different pathophysiology. We report case in which patient died of severe who was presumed have been caused by the administration nivolumab followed pazopanib for metastatic renal cell carcinoma. Case presentation A 74‐year‐old male carcinoma treated as third‐line treatment. However, subsequently discontinued, it thyroiditis. About 2 months after final...
Background/Aim: Measures to control adverse events (AEs) in the use of oral multi-kinase inhibitors (OMI) are important for continuation treatment. Patients and Methods: In this study, oncology pharmacists monitored symptoms patients receiving outpatient therapy with OMIs real-time using a smartphone Web app early detection/early treatment AEs. This feasibility study evaluated effects 10 compared data from who did not app. Results: group, grade 3 AEs were reported all on day their...
Essential thrombocythemia (ET) is a Philadelphia chromosome-negative myeloproliferative disorder that characterized by the overproduction of platelets and marked increase in numbers mature megakaryocytes present bone marrow. Thrombohemorrhagic disorders are major morbidities ET, especially those with mutations gene encoding Janus kinase 2 (JAK2). In this study, we report case an 18-year-old patient ET carrying JAK2 mutation who developed acute ST-elevation myocardial infarction (STEMI) 5...
【緒言】塩酸トラマドール(TRM)はWHO方式がん疼痛治療法の3段階除痛ラダーで第2段階の弱オピオイドに位置しており, 広くがん疼痛治療に用いられている薬剤である. 今回, 重症筋無力症(myasthenia gravis; MG)を有するがん疼痛患者に対してTRMを使用した症例を経験した. 【症例】70歳代, 女性. 子宮体癌, 右胸壁転移再発あり, 右胸部に疼痛の訴えがあったため, TRMカプセル75 mg/日で経口投与開始となり, 100 mg/日で疼痛コントロールは良好であった. 内服後一過性の筋脱力はみられたものの, 筋無力性クリーゼの出現はなく, 除痛効果を得ることが可能であったため報告する.
Thrombohemorrhagic disorders are the main cause of morbidities and mortalities essential thrombocythemia (ET), which typically observed at age 50–60 years rarely encountered in adolescence or childhood. Recently, anagrelide, a quinazinolone derivative, has been used as therapeutic agent for ET. Although it is to reduce platelet count, its cardiotoxicity reported. Here, we present an 18-year-old boy with ET who was treated anagrelide developed acute myocardial infarction. This presumed be...
This study aimed to clarify diverse values toward career visions for hospital pharmacists. A self-administered online questionnaire survey was delivered live and on-demand release attendees at a symposium about sustainable paths pharmacists the 32nd annual meeting of Japanese Society Pharmaceutical Health Care Sciences between September 23rd November 14th, 2022. Correspondence analyses text mining were conducted assess association participants' perspectives on their backgrounds consisting...